| Budget Amount *help |
¥17,940,000 (Direct Cost: ¥13,800,000、Indirect Cost: ¥4,140,000)
Fiscal Year 2014: ¥5,720,000 (Direct Cost: ¥4,400,000、Indirect Cost: ¥1,320,000)
Fiscal Year 2013: ¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2012: ¥6,760,000 (Direct Cost: ¥5,200,000、Indirect Cost: ¥1,560,000)
|
|---|
| Outline of Final Research Achievements |
The alpha-synuclein (SNCA) gene is a responsible gene for Parkinson’s disease (PD); and not only nucleotide variations but also overexpression of SNCA appears to be involved in PD. A specific inhibition against mutant SNCA genes carrying nucleotide variations may be feasible by an allele-specific RNAi; however, there is no method for restoring the SNCA overexpression to a normal level. In this study we showed that an atypical RNAi using siRNAs that confer a moderate level of gene silencing was capable of controlling overexpressed SNCA genes to return to a normal level; named ‘expression-control RNAi’ (ExCont-RNAi). To further assess its therapeutic effects, PD-model flies that carried the human SNCA gene underwent an ExCont-RNAi treatment. The treated PD-flies demonstrated a significant improvement in their motor function. Our current findings suggested that ExCont-RNAi might be capable of becoming a novel therapeutic procedure for PD with the SNCA overexpression.
|
